CHAD CREIGHTON to Molecular Targeted Therapy
This is a "connection" page, showing publications CHAD CREIGHTON has written about Molecular Targeted Therapy.
Connection Strength
0.577
-
Molecular classification and drug response prediction in cancer. Curr Drug Targets. 2012 Nov; 13(12):1488-94.
Score: 0.319
-
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20; 507(7492):315-22.
Score: 0.087
-
Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25.
Score: 0.079
-
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
Score: 0.029
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.023
-
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013 Apr; 138(2):369-81.
Score: 0.020
-
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
Score: 0.019